Piper Jaffray Companies set a $7.00 target price on ASLAN PHARMACEU/ADR (NASDAQ:ASLN) in a research note published on Monday, TipRanks reports. The brokerage currently has a buy rating on the stock.
A number of other brokerages have also recently commented on ASLN. HC Wainwright set a $9.00 target price on shares of ASLAN PHARMACEU/ADR and gave the company a buy rating in a report on Wednesday, June 5th. Zacks Investment Research cut shares of ASLAN PHARMACEU/ADR from a hold rating to a sell rating in a report on Thursday, August 15th. Finally, ValuEngine raised shares of ASLAN PHARMACEU/ADR from a hold rating to a buy rating in a report on Thursday, August 1st.
Shares of ASLN traded down $0.14 during mid-day trading on Monday, hitting $1.52. 5,447 shares of the company traded hands, compared to its average volume of 29,978. ASLAN PHARMACEU/ADR has a 1 year low of $1.50 and a 1 year high of $8.07. The stock has a market cap of $50.59 million, a price-to-earnings ratio of -1.09 and a beta of 2.39. The company has a debt-to-equity ratio of 0.81, a quick ratio of 3.80 and a current ratio of 2.54. The stock has a 50-day moving average price of $1.97 and a two-hundred day moving average price of $3.21.
An institutional investor recently raised its position in ASLAN PHARMACEU/ADR stock. Platinum Investment Management Ltd. raised its holdings in shares of ASLAN PHARMACEU/ADR (NASDAQ:ASLN) by 7.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 415,450 shares of the company’s stock after buying an additional 27,055 shares during the period. Platinum Investment Management Ltd. owned about 1.30% of ASLAN PHARMACEU/ADR worth $1,275,000 at the end of the most recent quarter. 7.16% of the stock is currently owned by institutional investors.
ASLAN PHARMACEU/ADR Company Profile
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4.
Receive News & Ratings for ASLAN PHARMACEU/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEU/ADR and related companies with MarketBeat.com's FREE daily email newsletter.